VYNE Therapeutics Inc. (VYNE) revealed encouraging outcomes from their Phase 1a clinical study of VYN202 this past Monday.
The initial Phase 1a study was a structured two-phase, dose-escalation trial conducted with healthy volunteers to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug VYN202.
Findings from the multiple ascending dose (MAD) section of the Phase 1a SAD (single ascending dose)/MAD study indicated that VYN202 exhibited a positive safety and tolerability profile, with no adverse events linked to the drug.
David Domzalski, President and Chief Executive Officer of VYNE, expressed enthusiasm, stating, "We are exceedingly pleased with the pharmacokinetic, pharmacodynamic, and safety data produced in this trial, which not only propels the ongoing development of VYN202 but also heightens our confidence in its potential to emerge as a pioneering treatment option for immune-mediated diseases."
